As the new tetravalent dengue fever vaccine from Takeda Pharmaceutical Company rapidly gains approvals around the globe, many interested parties were asking what this innovative disease protection would cost.
'We aim to make QDENGA® available to all eligible for vaccination in the countries where approved,' stated Takeda's presentation led by Ramona Sequeira, President, Global Portfolio Division, on March 15, 2023.
For example, Takeda disclosed these classifications:
New Dengue Vaccine Pricing Disclosed
Nirmatrelvir Cuts Risk for Post-COVID-19 Condition
Findings seen regardless of vaccination status and history of prior infection
Risk for GI Disorders Increased After Acute Phase of COVID-19
Risks were seen in patients who were not hospitalized, and increased across the severity spectrum of acute COVID-19